NEW YORK (Reuters) - A long-awaited experimental diabetes medicine from Eli Lilly & Co and Amylin Pharmaceuticals Inc that patients need to inject only once a week failed to match up to a rival ...
SAN DIEGO (AP) -- Diabetes drug maker Amylin Pharmaceuticals Inc. said Thursday that sales of its new drug Bydureon totaled $6.9 million in the first quarter, missing analysts' estimates. Amylin took ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback